Pfiz­er CEO points to IRA as a fac­tor that made Seagen an at­trac­tive tar­get

One of the rea­sons Pfiz­er sought to pur­chase Seagen, as part of a $43 bil­lion deal an­nounced this morn­ing, is that the Seat­tle-based biotech will be able to with­stand the com­ing head­winds of the In­fla­tion Re­duc­tion Act and the Medicare price ne­go­ti­a­tions that come with it.

Un­like some of his phar­ma CEO peers who have lam­bast­ed the new law, Pfiz­er CEO Al­bert Bourla told in­vestors on a call this morn­ing that there are two spe­cif­ic fac­tors per­tain­ing to the IRA that will ac­tu­al­ly help with the com­bo of Pfiz­er and Seagen mov­ing for­ward:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN